Nicotine Conjugate Vaccine as a Novel Approach to Smoking Cessation

Anne R. Ottney, Pharm.D


Pharmacotherapy. 2011;31(7):703-713. 

In This Article


Data from human studies discussing the pharmacokinetic properties of the 3′-AmNicrEPA vaccine are limited. A phase II immunogenicity and safety trial administered the vaccine to subjects at baseline, 1 month, 2 months, and 6 months.[14] After the first intramuscular injection of 3′-AmNic-rEPA 200 μg, nicotine-specific antibodies were detected in participants within 14 days of administration. Peak nicotine-specific antibody concentrations were reached approximately 2 weeks after the third 200-μg injection, correlating with a geometric mean nicotine-specific antibody concentration greater than 30 μg/ml (Figure 2). A pharmacokinetic study assessing another nicotine vaccine (CYT002-NicQb [also known as nicotine-Qbeta]; Cytos Biotechnology, Zurich, Switzerland, and Novartis Pharmaceuticals, Basel, Switzerland), which has a slightly different formulation from that of the 3′- AmNic-rEPA vaccine, determined that in healthy volunteers the half-life of nicotine-specific antibodies in the absence of the adjuvant, alum, was 47 days compared with 67 days in those individuals receiving the vaccine containing alum.[15]

Figure 2.

Mean antibody concentration by 3′-AmNic-rEPA dose or placebo over time. Arrows indicate injection times; dashed line indicates target nicotine-specific antibody concentration necessary to maximize vaccine efficacy. No antibody response was generated by placebo at any point during the study. IgG = immunoglobulin G. (Adapted from reference 14 with permission.)

Affinity of 3′-AmNic-rEPA for nicotine in the serum is high. An animal study demonstrated the mean ±; SD percentage of bound nicotine in the serum for animals receiving the 3′-AmNicrEPA vaccine was 94 ±;11% compared with 11 ±; 8% for the control group.[16] The unbound nicotine level in the serum in animals injected with the 3′-AmNic-rEPA vaccine was 5.1 ±3.2 ng/ml versus 17.7 ±3.8 ng/ml in controls (p<0.001). Animal models have shown that the elimination half-life of nicotine is prolonged by 3–6-fold in those who have been vaccinated, allowing nicotine levels to decrease more gradually.[17] The nicotine vaccine is capable of reducing nicotine distribution to the brain by up to 65%.[12]

Response to the 3′-AmNic-rEPA vaccine is maximized in those patients who are able to achieve high nicotine-specific antibody concentrations. Reference standards to classify nicotine antibody levels as high or low have been developed based on data from clinical trials. An antibody concentration greater than 25 μg/ml has been set as the optimal target for patients to achieve in order to enhance vaccine efficacy.[18] Data from a recent trial demonstrated that in patients receiving the 400-μg dose of the vaccine in each of five injections, antibody concentrations decreased below the 25-μg/ml threshold at study week 40, approximately 15 weeks after the fifth injection.[18] Despite a decline in therapeutic levels of antibodies, 6-month and 12-month abstinence rates were similar (17.6% and 15.7%, respectively).


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.